Secondary Progressive Multiple Sclerosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

SPMS MCID: SCN036 MIFTS: 45	Secondary Progressive Multiple Sclerosis (SPMS) Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

MalaCards integrated aliases for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis ¹¹ ⁵³ ¹⁴ ¹⁶ ³³

Multiple Sclerosis, Secondary Progressive ⁷¹

Multiple Sclerosis, Chronic Progressive ⁴³

Chronic Progressive Multiple Sclerosis ¹⁶

Secondary-Progressive Ms ¹¹

Spms ¹¹

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Immune diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Diseases of the nervous system

Multiple sclerosis or other white matter disorders

Multiple sclerosis

Secondary progressive multiple sclerosis

External Ids:

Disease Ontology ¹¹ DOID:0050783

MeSH ⁴³ D020528

SNOMED-CT ⁶⁸ 425500002

EFO ¹⁶ EFO_0003840 EFO_0008522

ICD11 ³³ 1045965709

UMLS ⁷¹ C0751965

Sources

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology: ¹¹ A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary: Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to relapsing-remitting multiple sclerosis and multiple sclerosis. An important gene associated with Secondary Progressive Multiple Sclerosis is MBP (Myelin Basic Protein), and among its related pathways/superpathways are superpathway of L-citrulline metabolism and Amino acid metabolism. The drugs Dalfampridine and Cladribine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, brain and spinal cord, and related phenotypes are immune system and hematopoietic system

Sources

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2	Multiple Sclerosis 3
Multiple Sclerosis 4	Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis	Primary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 390)

#	Related Disease	Score	Top Affiliating Genes
1	relapsing-remitting multiple sclerosis	31.8	MOG MIR142 MBP IFNB1 ICOSLG CCR6
2	multiple sclerosis	31.5	NEFL MOG MIR155 MIR146A MIR142 MBP
3	primary progressive multiple sclerosis	30.7	SERPINA3 S100B NEFL MOG MIR146A MIR142
4	neuromyelitis optica	30.6	S100B NEFL MOG MBP CD40LG
5	autoimmune disease	30.5	MOG MIR146A MBP IL2RB IFNB1 ICOSLG
6	nutritional deficiency disease	30.5	SERPINA3 MBP CCR6
7	mild cognitive impairment	30.5	SERPINA3 NEFL MIR15B MIR142
8	chickenpox	30.5	MOG IFNB1 CCR6
9	hypersensitivity reaction type iii disease	30.5	SERPINA3 ICOSLG CCR6
10	myelitis	30.4	MOG MBP IFNB1 CCR6
11	rubella	30.4	MOG IFNB1 CD40LG
12	primary cutaneous t-cell non-hodgkin lymphoma	30.4	MIR155 IL2RB CCR6
13	progressive multifocal leukoencephalopathy	30.3	MOG MBP IFNB1 ICOSLG CCR6
14	common cold	30.3	IFNB1 ICOSLG CD40LG CCR6
15	sjogren syndrome	30.3	ICOSLG CD40LG CCR6
16	mental depression	30.3	SERPINA3 PRODH MIR155 MIR142 CCR6
17	viral infectious disease	30.2	SERPINA3 MIR155 IFNB1 ICOSLG CD40LG CCR6
18	alzheimer disease, familial, 1	29.8	SERPINA3 S100B PRODH NEFL MIR485 MIR15B
19	spinal cord disease	29.7	SERPINA3 MOG MIR485 MIR155 MIR142 MBP
20	demyelinating disease	29.6	SERPINA3 PRODH NEFL MOG MIR92A1 MIR15B
21	ectodermal dysplasia-syndactyly syndrome 1	11.0
22	neonatal hypoxic and ischemic brain injury	10.4	MBP ENO2
23	pineocytoma	10.4	S100B ENO2
24	congenital epulis	10.4	SERPINA3 ENO2
25	epulis	10.4	SERPINA3 ENO2
26	histiocytosis	10.4	SERPINA3 S100B CCR6
27	cutaneous fibrous histiocytoma	10.4	SERPINA3 S100B ENO2
28	amelanotic melanoma	10.4	SERPINA3 S100B ENO2
29	acute retrobulbar neuritis	10.4	MOG MBP IFNB1
30	balo concentric sclerosis	10.4	MOG MBP IFNB1
31	internuclear ophthalmoplegia	10.4	MOG MBP IFNB1
32	rhabdomyosarcoma 2	10.4
33	gastric squamous cell carcinoma	10.4	SERPINA3 CCR6
34	postinfectious encephalitis	10.4	MOG MBP
35	autoimmune optic neuritis	10.4	MOG MBP
36	granular cell tumor	10.4	SERPINA3 S100B ENO2
37	critical covid-19	10.4	SERPINA3 IFNB1 CCR6
38	partial optic atrophy	10.4	SERPINA3 MOG
39	paranoid schizophrenia	10.4	SERPINA3 S100B PRODH
40	tropical spastic paraparesis	10.4	MBP IL2RB IFNB1
41	post-vaccinal encephalitis	10.4	MBP CCR6
42	malignant granular cell myoblastoma	10.4	SERPINA3 ENO2
43	jejunoileitis	10.4	S100B CCR6
44	primary thrombocytopenia	10.4	ICOSLG CD40LG CCR6
45	bacterial sepsis	10.4	IFNB1 ICOSLG CCR6
46	herpangina	10.4	IFNB1 ICOSLG CCR6
47	immunoglobulin alpha deficiency	10.4	ICOSLG CD40LG CCR6
48	posterior uveitis	10.4	IL2RB ICOSLG CCR6
49	post-cardiac arrest syndrome	10.4	S100B ENO2
50	dysentery	10.4	SERPINA3 ENO2 CCR6

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:

Sources

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	9.73	CCR6 CD40LG ICOSLG IFNB1 IL2RB MBP
2	hematopoietic system	MP:0005397	9.44	CCR6 CD40LG ICOSLG IFNB1 IL2RB MBP

Sources

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 229)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dalfampridine

Approved

Phase 4

504-24-5

1727

Cladribine

Approved, Investigational

Phase 4

4291-63-8

20279

Potassium Channel Blockers

Phase 4

Rituximab

Approved

Phase 2, Phase 3

174722-31-7

Carbamide peroxide

Approved

Phase 2, Phase 3

124-43-6

Acetaminophen

Approved

Phase 2, Phase 3

103-90-2

1983

Chlorpheniramine

Approved

Phase 2, Phase 3

113-92-8, 132-22-9

2725

Cianidanol

Approved, Withdrawn

Phase 2, Phase 3

154-23-4

9064

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Fexofenadine

Approved, Investigational

Phase 3

83799-24-0

3348

Melphalan

Approved

Phase 3

148-82-3

4053 460612

Alemtuzumab

Approved, Investigational

Phase 3

216503-57-0

Carmustine

Approved, Investigational

Phase 3

154-93-8

2578

Etoposide

Approved

Phase 3

33419-42-0

36462

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Ofatumumab

Approved

Phase 3

679818-59-8

Cytarabine

Approved, Investigational

Phase 3

147-94-4

6253

Desloratadine

Approved, Investigational

Phase 3

100643-71-8

124087

Simvastatin

Approved

Phase 3

79902-63-9

54454

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Ocrelizumab

Approved, Investigational

Phase 3

637334-45-3

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Diphenhydramine

Approved, Investigational

Phase 3

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 3

60-87-7

4927

Natalizumab

Approved, Investigational

Phase 3

189261-10-7

Dimethyl fumarate

Approved, Investigational

Phase 3

624-49-7

637568

Mitoxantrone

Approved, Investigational

Phase 3

70476-82-3, 65271-80-9

4212

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Biotin

Approved, Investigational, Nutraceutical

Phase 3

58-85-5

253 171548

Epigallocatechin gallate

Investigational

Phase 2, Phase 3

989-51-5

65064

Epigallocatechin

Experimental, Investigational

Phase 2, Phase 3

970-74-1

72277

Epicatechin

Investigational

Phase 2, Phase 3

490-46-0

58571364 72276

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Antirheumatic Agents

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Liver Extracts

Phase 2, Phase 3

Antioxidants

Phase 2, Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Neuroprotective Agents

Phase 3

Interventional clinical trials:

(show top 50) (show all 181)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open-label Multicenter Study to Assess Response to SARS-CoV-2 modRNA Vaccines in Participants With Secondary Progressive Multiple Sclerosis Treated With Mayzent (Siponimod)	Completed	NCT04792567	Phase 4	BAF312;Baseline disease modifying therapies (DMTs)
2	A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis	Completed	NCT02208050	Phase 4	Fampridine;Placebo
3	An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis	Completed	NCT02683863	Phase 4	BG00012 (DMF) (Tecfidera®.)
4	Open-label, Single-blind, Observational, Comparative, Prospective, 36-month, Longitudinal, Controlled Study to Assess Efficacy of Siponimod (Mayzent®) on Microglia in Patients With Active Secondary Progressive Forms of Multiple Sclerosis	Recruiting	NCT04925557	Phase 4	Mayzent;Ocrevus
5	A Prospective Biomarker Study in Active Secondary Progressive Multiple Sclerosis (SPMS)Subjects Treated With Cladribine Tablets	Recruiting	NCT04550455	Phase 4	Cladribine Tablets
6	A Prospective Study Evaluating the Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in Multiple Sclerosis Using PET-MRI With 18F-DPA714	Unknown status	NCT03691077	Phase 3	Ocrelizumab
7	Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study	Unknown status	NCT02220933	Phase 3	MD1003 100mg capsule;Placebo
8	Comparison of Expanded Disability Status Scale, Gad-enhanced Brain Lesions, Annualized Relapse Rate, and Side Effects Between Active Secondary Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate	Completed	NCT03315923	Phase 2, Phase 3	Rituximab;Glatiramer Acetate
9	A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis	Completed	NCT00869726	Phase 2, Phase 3	dirucotide;Placebo
10	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension	Completed	NCT01917019	Phase 3	Placebo;BIIB041 (fampridine)
11	A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study	Completed	NCT00241254	Phase 3	Cyclophosphamide (drug);Methylprednisolone (drug)
12	A 96 Week, Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled, 2 Parallel-groups, Phase 3 Study to Compare Efficacy and Safety of Masitinib 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis	Completed	NCT01433497	Phase 3	Masitinib;Placebo
13	Lipoic Acid for Neuroprotection in Secondary Progressive MS	Completed	NCT01188811	Phase 2, Phase 3	lipoic acid;Placebo
14	A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis	Completed	NCT00087529	Phase 2, Phase 3	placebo;rituximab
15	Monocentric, Prospective, Doubleblind, Randomised/Stratified, Placebocontrolled Two-arm Study to Evaluate the Effect of Sunphenon EGCg (Main Component Epigallocatechin-Gallat) on the Increase of Brain Atrophy in the Cerebral Magnetic Resonance Tomography in a 36-months Treatment Time in Patients With Primary or Secondary Chronic-progressive Multiple Sclerosis	Completed	NCT00799890	Phase 2, Phase 3	Sunphenon EGCG;Placebo
16	Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Recruiting	NCT04688788	Phase 3	Rituximab;Ocrelizumab;Fexofenadine;Paracetamol;Methylprednisolone
17	A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis	Recruiting	NCT04411641	Phase 3	Tolebrutinib;Placebo to match Tolebrutinib
18	A Multicenter Randomized Controlled Trial of Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis (ITN077AI)	Recruiting	NCT04047628	Phase 3
19	Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years	Recruiting	NCT03653273	Phase 3	DMT continuation
20	A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/Day Versus Placebo in the Treatment of Patients With Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse	Recruiting	NCT05441488	Phase 3	Placebo;Masitinib (4.5)
21	ChariotMS - A National (UK) Phase IIb, Multi-centre, Randomised, Double-blind, Placebo Controlled (1:1) Efficacy Trial With Cost-utility Analysis of Cladribine Tablets (3.5mg/kg Over Two Years) in People With Advanced Multiple Sclerosis. Is Cladribine Superior to Placebo in Protecting Upper Limb Function?	Recruiting	NCT04695080	Phase 2, Phase 3	Cladribine (MAVENCLAD®);Placebo
22	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	Recruiting	NCT05232825	Phase 3	Ocrelizumab IV;Ocrelizumab SC;Methylprednisolone IV;Diphenhydramine IV;Dexamethasone given orally;Desloratadine given orally
23	A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Recruiting	NCT04035005	Phase 3	Ocrelizumab;Placebo
24	A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)	Recruiting	NCT04458051	Phase 3	Tolebrutinib;Placebo
25	A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis.	Recruiting	NCT04544449	Phase 3	fenebrutinib;ocrelizumab;placebo
26	A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Recruiting	NCT04548999	Phase 3	Ocrelizumab;Antihistamine;Methylprednisolone
27	A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis	Recruiting	NCT02057159	Phase 2, Phase 3
28	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.	Active, not recruiting	NCT01665144	Phase 3	BAF312;Placebo
29	A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability	Active, not recruiting	NCT03387670	Phase 3	Simvastatin;Placebo
30	An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis	Active, not recruiting	NCT02688985	Phase 3	Ocrelizumab;Methyloprednisolone;Antihistamine
31	An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis	Active, not recruiting	NCT03523858	Phase 3	Ocrelizumab
32	A Phase III, Multicentre, Randomized, Parallel-group, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Active, not recruiting	NCT01194570	Phase 3	Ocrelizumab
33	A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis	Terminated	NCT00146159	Phase 3	Mitoxantrone
34	An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis	Terminated	NCT00870155	Phase 2, Phase 3	dirucotide
35	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, With Optional Open-Label Extension	Terminated	NCT01416181	Phase 3	natalizumab;Placebo
36	A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis	Terminated	NCT00468611	Phase 3	MBP8298
37	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	Terminated	NCT02430532	Phase 3	dimethyl fumarate
38	A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis	Terminated	NCT00731692	Phase 3	FTY720;Placebo
39	Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study	Terminated	NCT02936037	Phase 3	MD1003 100mg capsule;PLACEBO
40	A Scandinavian, Randomized, Rater-blinded Study of Single and Double-dose Betaferon in Patients With Early Secondary Progressive Multiple Sclerosis	Withdrawn	NCT00313976	Phase 3	Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
41	A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage	Unknown status	NCT03896217	Phase 2	Simvastatin
42	A Randomised, Double-blind, Placebo-controlled Study of AIMSPRO in Treating Bladder Dysfunction in Secondary Progressive Multiple Sclerosis	Unknown status	NCT01228396	Phase 2	Hyperimmune caprine serum against HIV lysate
43	A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.	Unknown status	NCT01466114	Phase 2	estriol;Norethindrone
44	Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis	Unknown status	NCT02273635	Phase 1, Phase 2	Andrographolides;placebo
45	Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis	Unknown status	NCT01144117	Phase 2	Erythropoietin
46	Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)	Unknown status	NCT01815632	Phase 2
47	Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica	Unknown status	NCT01364246	Phase 1, Phase 2
48	A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination	Unknown status	NCT02149706	Phase 2
49	A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis	Completed	NCT01684761	Phase 2
50	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Completed	NCT01910259	Phase 2	Amiloride;Riluzole;Fluoxetine;Placebo

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Sources

Genetic Tests for Secondary Progressive Multiple Sclerosis

Sources

Anatomical Context for Secondary Progressive Multiple Sclerosis

Organs/tissues related to Secondary Progressive Multiple Sclerosis:

MalaCards : Bone Marrow, Brain, Spinal Cord, Bone, T Cells, Liver, Myeloid

Sources

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 3534)

#	Title	Authors	PMID	Year
1	[Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]. ⁵³ ⁶²	Patrucco L...Cristiano E	20443171	2010
2	Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. ⁵³ ⁶²	Bitsch A...Weber F	15645350	2004
3	Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. ⁵³ ⁶²	Warren KG...Wucherpfennig KW	9395124	1997
4	Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. ⁵³ ⁶²	Jongen PJ...Hommes OR	9343121	1997
5	Myelin basic protein gene polymorphism is not associated with chronic progressive multiple sclerosis. ⁵³ ⁶²	Vandevyver C...Raus J	7515903	1994
6	Defective CD3 mediated proliferation and LPS responsiveness in multiple sclerosis. ⁵³ ⁶²	Brod SA...Scott M	7520286	1994
7	Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. ⁵³ ⁶²	Trotter JL...van der Veen RC	2056069	1991
8	Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility. ⁵³ ⁶²	Peter JB...Tourtellotte WW	1985276	1991
9	Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma. ⁶²	Basavarajappa D...Graham SL	36204852	2023
10	Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension. ⁶²	Diaz Del Campo LS...Briones AM	36337053	2023
11	Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies. ⁶²	Ziemssen T...Hach T	36414428	2023
12	Multi-omics analysis of magnetically levitated plasma biomolecules. ⁶²	Ashkarran AA...Mahmoudi M	36403493	2023
13	Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis. ⁶²	Chang I...Zhu B	36131595	2022
14	Density strips: visualisation of uncertainty in clinical data summaries and research findings. ⁶²	Weir CJ...Bowman AW	34933930	2022
15	Specialized pro-resolvin mediators induce cell growth and improve wound repair in intestinal epithelial Caco-2 cell cultures. ⁶²	Storniolo CE...Moreno JJ	36427427	2022
16	Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. ⁶²	Martins P...Monteiro I	36454397	2022
17	Quantitative 7T sodium magnetic resonance imaging of the human brain using a 32-channel phased-array head coil: Application to patients with secondary progressive multiple sclerosis. ⁶²	Wilferth T...Schmidt M	35892310	2022
18	Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register. ⁶²	Iaffaldano P...Trojano M	35971322	2022
19	Analysis and prediction of second primary malignancy in patients with breast cancer. ⁶²	Long Q...Li H	36381252	2022
20	The regulatory effect of specialized pro-resolving mediators on immune cells. ⁶²	Pan G...Wu Y	36411650	2022
21	Targeting inflammation and pro-resolving mediators with Anetholea anisita extract to improve scalp condition. ⁶²	Duroux R...Attia J	35979727	2022
22	Influence of Cardiovascular Risk Factors in Early Relapsing-Remitting Multiple Sclerosis: A Retrospective Analysis. ⁶²	Arroyo-Pereiro P...Martinez-Yelamos S	36470228	2022
23	Muscle architecture and its relationship with lower extremity muscle strength in multiple sclerosis. ⁶²	Kirmaci ZIK...Ergun N	34417688	2022
24	Associations between corpus callosum damage, clinical disability, and surface-based homologous inter-hemispheric connectivity in multiple sclerosis. ⁶²	Russo AW...Klawiter EC	35536387	2022
25	Human Neural Stem Cell-Based Drug Product: Clinical and Nonclinical Characterization. ⁶²	Profico DC...Vescovi AL	36362211	2022
26	Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study. ⁶²	Vistbakka J...Hagman S	36084364	2022
27	Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple sclerosis? ⁶²	Arsenault S...Moore CS	36126539	2022
28	Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis. ⁶²	Regner-Nelke L...Meuth SG	36336685	2022
29	Self-efficacy training as an adjunct to exercise in a person with progressive multiple sclerosis: a case report. ⁶²	Eustis H...Plummer P	34081567	2022
30	Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis. ⁶²	El Ayoubi NK...Khoury SJ	36229190	2022
31	Synchronous Second Primary Cancers of Hypopharyngeal Carcinoma in the Image-Enhanced Endoscopy Era. ⁶²	Luo X...Yi J	36321782	2022
32	Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. ⁶²	Rock CB...Gaffney DK	36420188	2022
33	Ginsenoside Rg1 promotes remyelination and functional recovery in demyelinating disease by enhancing oligodendrocyte precursor cells-mediated myelin repair. ⁶²	Liu L...Li Q	35994846	2022
34	Olfactory Dysfunction Reflects Disease Progression in Japanese Patients with Multiple Sclerosis. ⁶²	Okada K...Tahara M	35400704	2022
35	Psychological flexibility, distress, and quality of life in secondary progressive multiple sclerosis: A cross-sectional study. ⁶²	Meek C...Moghaddam N	36116384	2022
36	Characterizing microglial gene expression in a model of secondary progressive multiple sclerosis. ⁶²	Vainchtein ID...Kooistra SM	36377669	2022
37	Working memory dysfunction differs between secondary progressive and relapsing multiple sclerosis: Effects of clinical phenotype, age, disease duration, and disability. ⁶²	Pourmohammadi A...Sanayei M	36436396	2022
38	Anti-inflammatory effects of siponimod on astrocytes. ⁶²	Ogasawara A...Tanaka F	35940437	2022
39	The nine hole peg test as an outcome measure in progressive MS trials. ⁶²	Koch MW...Cutter G	36462470	2022
40	MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis. ⁶²	Dilwali S...Waubant E	36396446	2022
41	Inflammation and Infection in Pain and the Role of GPR37. ⁶²	Zhang Q...Ji RR	36430912	2022
42	Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials. ⁶²	Yang B...Su KP	36341839	2022
43	Increased cytomegalovirus immune responses at disease onset are protective in the long-term prognosis of patients with multiple sclerosis. ⁶²	Comabella M...Montalban X	36344261	2022
44	Limb apraxia in individuals with multiple sclerosis: Is there a role of semi-immersive virtual reality in treating the Cinderella of neuropsychology? ⁶²	Maggio MG...Calabro RS	36417812	2022
45	miR-181a-5p is a potential candidate epigenetic biomarker in multiple sclerosis. ⁶²	Edgunlu TG...Erdal ME	36103723	2022
46	Niclosamide targets the dynamic progression of macrophages for the resolution of endometriosis in a mouse model. ⁶²	Zhao L...Hayashi K	36369244	2022
47	Unraveling the genetics of polyamine metabolism in barley for senescence-related crop improvement. ⁶²	Tanwar UK...Sobieszczuk-Nowicka E	36075308	2022
48	External validation of a clinical prediction model in multiple sclerosis. ⁶²	Moradi N...Kalincik T	36448727	2022
49	Toward Precision Phenotyping of Multiple Sclerosis. ⁶²	Pitt D...Lincoln MR	36041861	2022
50	Novel pro-resolving lipid mediator mimetic 3-oxa-PD1n-3 DPA reduces acute and chronic itch by modulating excitatory and inhibitory synaptic transmission and astroglial secretion of lipocalin-2 in mice. ⁶²	Furutani K...Ji RR	36378290	2022

Sources

Genes for Secondary Progressive Multiple Sclerosis

Genes related to Secondary Progressive Multiple Sclerosis (0 elite genes):

(show all 34)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MBP	Myelin Basic Protein	Protein Coding	28.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7515903 9395124 7520286 (more) 9343121
2	IFNB1	Interferon Beta 1	Protein Coding	24.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20443171 15645350
3	CD40LG	CD40 Ligand	Protein Coding	12.54	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
4	S100B	S100 Calcium Binding Protein B	Protein Coding	12.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	ENO2	Enolase 2	Protein Coding	11.15	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	10.76	DISEASES inferred ¹⁴ ¹⁴
7	IL2RB	Interleukin 2 Receptor Subunit Beta	Protein Coding	9.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1985276 2056069
8	MIR92A1	MicroRNA 92a-1	RNA Gene	8.73	DISEASES inferred ¹⁴ ¹⁴
9	PRODH	Proline Dehydrogenase 1	Protein Coding	8.51	DISEASES inferred ¹⁴ ¹⁴
10	MIR142	MicroRNA 142	RNA Gene	8.09	DISEASES inferred ¹⁴ ¹⁴
11	SERPINA3	Serpin Family A Member 3	Protein Coding	8.03	DISEASES inferred ¹⁴ ¹⁴
12	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	7.94	DISEASES inferred ¹⁴ ¹⁴
13	MOG	Myelin Oligodendrocyte Glycoprotein	Protein Coding	7.92	DISEASES inferred ¹⁴
14	MIR155	MicroRNA 155	RNA Gene	7.8	DISEASES inferred ¹⁴ ¹⁴
15	SMS	Spermine Synthase	Protein Coding	7.75	DISEASES inferred ¹⁴
16	MIR15B	MicroRNA 15b	RNA Gene	7.74	DISEASES inferred ¹⁴ ¹⁴
17	SRM	Spermidine Synthase	Protein Coding	7.58	DISEASES inferred ¹⁴
18	MIR146A	MicroRNA 146a	RNA Gene	7.49	DISEASES inferred ¹⁴ ¹⁴
19	NEFL	Neurofilament Light Chain	Protein Coding	7.33	DISEASES inferred ¹⁴
20	MIR485	MicroRNA 485	RNA Gene	7.32	DISEASES inferred ¹⁴ ¹⁴
21	MIR191	MicroRNA 191	RNA Gene	7.3	DISEASES inferred ¹⁴ ¹⁴
22	AMD1	Adenosylmethionine Decarboxylase 1	Protein Coding	7.24	DISEASES inferred ¹⁴
23	MIR532	MicroRNA 532	RNA Gene	7.18	DISEASES inferred ¹⁴ ¹⁴
24	AZIN2	Antizyme Inhibitor 2	Protein Coding	7.17	DISEASES inferred ¹⁴
25	MIR337	MicroRNA 337	RNA Gene	7.14	DISEASES inferred ¹⁴ ¹⁴
26	MIR125A	MicroRNA 125a	RNA Gene	7.11	DISEASES inferred ¹⁴ ¹⁴
27	CD4	CD4 Molecule	Protein Coding	7.03	DISEASES inferred ¹⁴
28	S1PR5	Sphingosine-1-Phosphate Receptor 5	Protein Coding	6.93	DISEASES inferred ¹⁴
29	ODC1	Ornithine Decarboxylase 1	Protein Coding	6.93	DISEASES inferred ¹⁴
30	MIR132	MicroRNA 132	RNA Gene	6.84	DISEASES inferred ¹⁴ ¹⁴
31	MIR106B	MicroRNA 106b	RNA Gene	6.74	DISEASES inferred ¹⁴ ¹⁴
32	CD8A	CD8a Molecule	Protein Coding	6.73	DISEASES inferred ¹⁴
33	AQP4	Aquaporin 4	Protein Coding	6.63	DISEASES inferred ¹⁴
34	S1PR1	Sphingosine-1-Phosphate Receptor 1	Protein Coding	6.59	DISEASES inferred ¹⁴

Sources

Variations for Secondary Progressive Multiple Sclerosis

Sources

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Sources

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	superpathway of L-citrulline metabolism ⁶¹ Show member pathways citrulline-nitric oxide cycle ⁶¹ Effects of nitric oxide ⁷⁴ L-citrulline biosynthesis ⁶¹ nitric oxide biosynthesis II (mammals) ⁶¹ Nitric oxide metabolism in cystic fibrosis ⁷⁴ urea cycle ⁶¹ Urea cycle ⁶⁶ Urea cycle and associated pathways ⁷⁴ Urea cycle and metabolism of amino groups ⁷⁴	11.32	SRM SMS PRODH
2	Amino acid metabolism ⁷⁴ Show member pathways Amino acid metabolism pathway excerpt: histidine catabolism extension ⁷⁴	11.11	SRM SMS PRODH
3	Neural Stem Cells and Lineage-specific Markers ⁶⁵	10.7	S100B NEFL MOG

Sources

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.83	SERPINA3 S100B MIR92A1 MIR485 MIR15B MIR146A
2	RISC complex	GO:0016442	9.4	MIR92A1 MIR485 MIR15B MIR155 MIR146A MIR142

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	polyamine metabolic process	GO:0006595	9.46	SRM SMS
2	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.43	MIR92A1 MIR15B MIR146A
3	positive regulation of metalloendopeptidase activity	GO:1904685	9.13	MIR92A1 MBP
4	negative regulation of inflammatory response	GO:0050728	8.92	MIR92A1 MIR15B MIR146A MIR142

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.35	MIR92A1 MIR15B MIR155 MIR146A MIR142
2	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR92A1 MIR485 MIR15B MIR155 MIR146A MIR142